All filters
Abstracts
Growth recovery among Asian children with perinatally acquired HIV infection on first-line combination antiretroviral therapy
T. Sudjaritruk Reviews in Antiviral Therapy & Infectious Diseases 3, 2021
Presented at:
APACC 2021
Abstracts
A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic
A. Chrysostomou  Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene
M. Bellocchi Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
High sensitivity pool testing for SARS-CoV-2 RNA from throat wash and nasopharyngeal swabs
M. Dusek Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Significant SARS-CoV-2 RNA decay during remdesivir treatment in real life COVID-19 hospitalized patients
L. Piermatteo Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers
S. Marot Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Long-acting HIV capsid inhibitor effective as PrEP in a SHIV rhesus macaque model
E. Bekerman Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Prevalence of genotypic baseline risk factors of cabotegravir+rilpivirine failure among ARV-naïve patients
C. Charpentier Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
HIV-1 subtypes B, G and CRF02_AG transmission cluster in Migrants population followed in Portugal based on sequence data
V. Pimentel Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Low prevalence of archived M184V/I mutations in 3 HIV-1 suppressed, switch studies
R. Wang Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Kinetics of archived M184V mutation in HIV-DNA from highly experienced HIV-infected patients with sustained viral suppression
R. Palich Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
HIV-1 reverse transcriptase natural polymorphism V106I does not alter the susceptibility and the genetic barrier to resistance to Doravirine in vitro.
F. Giammarino Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Virological efficacy of switch to 3TC/DTG in a real life cohort of suppressed HIV-1 patients with or without past M184V – The LAMRES Study
M. Santoro Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Exploratory Analysis of Baseline Phenotypic and Genotypic Parameters in Relation to Antiviral Activity for Fostemsavir (FTR) in Heavily Treatment-Experienced (HTE) Patients in the Phase 3 BRIGHTE Study
A. Merritt Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Determinants of HIV-1 late presentation in patients followed in Europe
M. Miranda Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Exploration of the possible mechanisms leading to greater mortality in people with limited drug options (LDO)
A. Cozzi-Lepri Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG+3TC or ATV/r+3TC dual therapy
F. Dragoni Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Usefulness of next-generation sequencing on PBMC samples and HIV-1 DNA quantification in management of treatment optimization in HIV-1 infected virologically suppressed individuals
D. Armenia Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
APOBEC editing in HIV DNA proviral vif and pol long-reads issued from virologically-suppressed patients included in the ANRS LAMIDOL trial
C. Charpentier Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
A Multi-Allelic Molecular-Beacon-Based Real-Time RT-PCR Assay for the Detection of the Coronavirus SARS-CoV-2 from Clinical Samples
A. Chrysostomou Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Use of Fibroquel® (type I polymerized collagen) in patients with hypoxemic inflammatory pneumonia secondary to COVID-19 in Veracruz, Mexico.
L. Del Carpio-Orantes Reviews in Antiviral Therapy & Infectious Diseases 2, 2021  
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
Longitudinal Evaluation of Sequencing Quality in EQA-Schemes from 2014 to 2020
M. Schütze Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021
Abstracts
PK-virological algorithm to target risk of resistance among key populations in Togo
V. Ferré Reviews in Antiviral Therapy & Infectious Diseases 2, 2021
Presented at:
European Meeting on HIV & Hepatitis 2021